New ELISA technique for analysis of p53 protein/DNA binding properties

Journal of Immunological Methods

Volumn 267, Issue 2, 2002, Pages 227-235

  Jagelská, Eva ^a   Brázda, Václav ^a   Pospisilová, Sarka ^b   Vojtesek, Borivoj ^b   Palecek, Emil ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

DNA binding; ELISA; P53

Indexed keywords

DNA; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; PROTEIN P53; STREPTAVIDIN;

ACCURACY; ARTICLE; CONSENSUS SEQUENCE; DNA PROTEIN COMPLEX; ENZYME LINKED IMMUNOSORBENT ASSAY; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; RADIOACTIVITY; RELIABILITY; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BINDING SITES; BINDING, COMPETITIVE; CONSENSUS SEQUENCE; DNA; DNA, SUPERHELICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PROTEIN BINDING; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037106029     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(02)00182-5     Document Type: Article

References (26)

1. Specific modulation of p53 binding to consensus sequence within supercoiled DNA by monoclonal antibodies
2. Crystal structure of a p53 tumor suppressor-DNA complex: Detailed view of the mutation hotspots
3. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
4. Life and death by p53
5. IARC Database of p53 gene mutations in human tumors and cell lines: Updated compilation, revised formats and new visualisation tools
6. Regulation of p53 protein function through alterations in protein-folding pathways
7. Serum p53 antibodies in small cell lung cancer: The lack of prognostic relevance
8. Covalent and noncovalent modifiers of the p53 protein
9. DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53
10. Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53
11. P53 Antibodies in patients with various types of cancer: Assay, identification, and characterization
12. High rate of p53 overexpression in head and neck carcinomas detected with a refined ELISA
13. Head and neck cancer and p53-immunogenicity
14. Analysis of p53 expression in human tumours: An antibody raised against human p53 expressed in Escherichia coli
15. Serum anti-p53 antibodies and p53 protein status in the sera and tumors from bladder cancer patients
16. P53 Derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence
17. Tumor suppressor protein p53 binds preferentially to supercoiled DNA
18. Binding of p53 and its core domain to supercoiled DNA
19. Precise characterisation of monoclonal antibodies to the C-terminal region of p53 protein using the PEPSCAN ELISA technique and a new non-radioactive gel shift assay
20. Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist?
21. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: Insights into antibody-peptide interactions
22. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53
23. Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique
24. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein
25. Quantification of p53 expression in the nervous system